Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.

HER2 HER2-targeted therapy androgen deprivation therapy androgen receptor salivary duct carcinoma

Journal

Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808

Informations de publication

Date de publication:
2022
Historique:
received: 23 03 2022
accepted: 27 07 2022
entrez: 12 9 2022
pubmed: 13 9 2022
medline: 13 9 2022
Statut: epublish

Résumé

The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent or metastatic (LA/RM) salivary duct carcinoma (SDC) have been reported in prospective studies. However, the survival benefit of these therapies to conventional therapy remains controversial, and whether HER2-targeted therapy or ADT should be chosen in HER2- and androgen receptor (AR)-positive SDC patients remains unknown. Overall, 323 LA/RM SDC patients treated at seven institutions between August 1992 and June 2020 were retrospectively enrolled. The primary aim was to analyze the effect of HER2-targeted therapy and ADT on overall survival from the diagnosis of LA/RM disease to death from any cause (OS1). The secondary indicators included the overall response rate (ORR), clinical benefit rate (CBR), overall survival from therapy initiation for LA/RM disease (OS2), progression-free survival (PFS), time to second progression (PFS2), duration of response (DoR), and duration of clinical benefit (DoCB) of HER2-targeted therapy or ADT as first-line therapy for HER2-positive/AR-positive SDC. Patients treated with HER2-targeted therapy or ADT had longer OS1 than those treated without these therapies (Median OS1: historical control, 21.6 months; HER2-targeted therapy, 50.6 months; ADT, 32.8 months; HER2-targeted therapy followed by ADT, 42.4 months; and ADT followed by HER2-targeted therapy, 45.2 months, Patients treated with HER2-targeted therapy and ADT showed longer survival in LA/RM SDC. HER2-targeted therapy can be recommended prior to ADT for HER2-positive/AR-positive SDC. It is warranted to establish a biomarker that could predict the efficacy of clinical benefit or better response in ADT.

Sections du résumé

Background UNASSIGNED
The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent or metastatic (LA/RM) salivary duct carcinoma (SDC) have been reported in prospective studies. However, the survival benefit of these therapies to conventional therapy remains controversial, and whether HER2-targeted therapy or ADT should be chosen in HER2- and androgen receptor (AR)-positive SDC patients remains unknown.
Methods UNASSIGNED
Overall, 323 LA/RM SDC patients treated at seven institutions between August 1992 and June 2020 were retrospectively enrolled. The primary aim was to analyze the effect of HER2-targeted therapy and ADT on overall survival from the diagnosis of LA/RM disease to death from any cause (OS1). The secondary indicators included the overall response rate (ORR), clinical benefit rate (CBR), overall survival from therapy initiation for LA/RM disease (OS2), progression-free survival (PFS), time to second progression (PFS2), duration of response (DoR), and duration of clinical benefit (DoCB) of HER2-targeted therapy or ADT as first-line therapy for HER2-positive/AR-positive SDC.
Results UNASSIGNED
Patients treated with HER2-targeted therapy or ADT had longer OS1 than those treated without these therapies (Median OS1: historical control, 21.6 months; HER2-targeted therapy, 50.6 months; ADT, 32.8 months; HER2-targeted therapy followed by ADT, 42.4 months; and ADT followed by HER2-targeted therapy, 45.2 months,
Conclusion UNASSIGNED
Patients treated with HER2-targeted therapy and ADT showed longer survival in LA/RM SDC. HER2-targeted therapy can be recommended prior to ADT for HER2-positive/AR-positive SDC. It is warranted to establish a biomarker that could predict the efficacy of clinical benefit or better response in ADT.

Identifiants

DOI: 10.1177/17588359221119538 PMID: 36090801 PMC: PMC9459484
pubmed: 36090801
doi: 10.1177/17588359221119538
pii: 10.1177_17588359221119538
pmc: PMC9459484
doi:

Types de publication

Journal Article

Langues

eng

Pagination

17588359221119538

Informations de copyright

© The Author(s), 2022.

Déclaration de conflit d'intérêts

Competing interests: The authors declare that there is no conflict of interest.

Références

Hum Pathol. 2019 Nov;93:37-47
pubmed: 31437521
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Ann Oncol. 2020 Mar;31(3):412-421
pubmed: 32067683
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Ann Oncol. 2018 Apr 1;29(4):979-984
pubmed: 29211833
Acta Otolaryngol. 2016 Sep;136(9):948-51
pubmed: 27094013
J Clin Oncol. 2019 Jan 10;37(2):125-134
pubmed: 30452336
Ann Transl Med. 2020 Nov;8(21):1355
pubmed: 33313100
J Clin Oncol. 2021 Dec 20;39(36):4061-4068
pubmed: 34597119
Oral Oncol. 2022 Feb;125:105703
pubmed: 34995931
J Clin Oncol. 2021 Dec 20;39(36):4069-4072
pubmed: 34597118
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Eur J Cancer. 2019 Mar;110:62-70
pubmed: 30771738
JCO Precis Oncol. 2021 Nov;5:1526-1527
pubmed: 34994640
In Vivo. 2019 May-Jun;33(3):843-853
pubmed: 31028207
Head Neck. 2016 May;38(5):724-31
pubmed: 25522335
Int J Cancer. 2020 Jun 1;146(11):3196-3206
pubmed: 31745978
Int J Cancer. 2018 Aug 15;143(4):758-766
pubmed: 29492965
Sci Rep. 2020 Oct 12;10(1):16988
pubmed: 33046752
Med Oncol. 2021 Sep 22;38(11):128
pubmed: 34550483
Curr Opin Otolaryngol Head Neck Surg. 2018 Apr;26(2):142-151
pubmed: 29373327
Head Neck. 2018 Mar;40(3):605-613
pubmed: 29272069
Ann Oncol. 2019 Nov 1;30(11):1821-1830
pubmed: 31504139
Cancer Cytopathol. 2020 Oct;128(10):693-703
pubmed: 32421944
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Head Neck. 2014 May;36(5):694-701
pubmed: 23606370
Oral Oncol. 2003 Oct;39(7):724-7
pubmed: 12907212
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Front Oncol. 2019 Aug 02;9:701
pubmed: 31428578
Clin Cancer Res. 2016 Sep 15;22(18):4623-33
pubmed: 27103403
Cancer. 2020 May 15;126(10):2153-2162
pubmed: 32097509
J Clin Oncol. 2022 Jul 22;:JCO2200229
pubmed: 35867947
Ann Oncol. 2018 Jul;29(7):1599-1601
pubmed: 32138836
Oncologist. 2013;18(3):294-300
pubmed: 23429737
Oral Oncol. 2017 Sep;72:198-200
pubmed: 28673692
Cancers (Basel). 2021 Jul 14;13(14):
pubmed: 34298742
J Clin Oncol. 2018 Aug 20;36(24):2532-2537
pubmed: 29989854
Cancer Treat Rev. 2020 Sep;89:102069
pubmed: 32717621
Mod Pathol. 2020 Oct;33(10):1896-1909
pubmed: 32457410
Cancer. 2022 Feb 1;128(3):509-518
pubmed: 34661906
Front Oncol. 2022 Feb 03;11:779882
pubmed: 35186711
Oral Oncol. 2017 Aug;71:41-46
pubmed: 28688689
Oncotarget. 2017 Aug 2;8(35):59023-59035
pubmed: 28938615
J Clin Oncol. 2021 Jun 10;39(17):1909-1941
pubmed: 33900808
Am J Clin Oncol. 2018 Nov;41(11):1083-1088
pubmed: 29462123
Oncologist. 2020 Jul;25(7):598-608
pubmed: 32310325

Auteurs

Daisuke Kawakita (D)

Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Toshitaka Nagao (T)

Department of Anatomic Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Hideaki Takahashi (H)

Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, School of Medicine, Yokohama, Japan.

Satoshi Kano (S)

Department of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

Yoshitaka Honma (Y)

Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.

Hideaki Hirai (H)

Department of Anatomic Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Natsuki Saigusa (N)

Department of Anatomic Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Kohei Akazawa (K)

Department of Medical Informatics, Niigata University Medical and Dental Hospital, Chuo-ku, Niigata, Japan.

Kaori Tani (K)

Department of Medical Informatics, Niigata University Medical and Dental Hospital, Chuo-ku, Niigata, Japan.

Hiroya Ojiri (H)

Department of Radiology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.

Kiyoaki Tsukahara (K)

Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Hiroyuki Ozawa (H)

Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Kenji Okami (K)

Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara, Japan.

Takahito Kondo (T)

Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji, Japan.

Takafumi Togashi (T)

Department of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan.

Chihiro Fushimi (C)

Department of Head and Neck Oncology and Surgery, International University of Health and Welfare, Mita Hospital, Minato-ku, Tokyo, Japan.

Tomotaka Shimura (T)

Department of Otolaryngology, Showa University Fujigaoka Hospital, Aoba-ku, Yokohama, Japan.

Akira Shimizu (A)

Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Isaku Okamoto (I)

Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Takuro Okada (T)

Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Yorihisa Imanishi (Y)

Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Yoshihiro Watanabe (Y)

Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Kuninori Otsuka (K)

Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Akihiro Sakai (A)

Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara, Japan.

Koji Ebisumoto (K)

Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara, Japan.

Yuichiro Sato (Y)

Department of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan.

Keisuke Yamazaki (K)

Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Chuo-ku, Niigata, Japan.

Yushi Ueki (Y)

Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Chuo-ku, Niigata, Japan.

Toyoyuki Hanazawa (T)

Department of Otorhinolaryngology/Head & Neck Surgery, Chiba University Graduate School of Medicine, Chuo-ku, Chiba, Japan.

Yuki Saito (Y)

Department of Otolaryngology - Head and Neck Surgery, Faculty of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Mizuo Ando (M)

Department of Otorhinolaryngology/Head & Neck Surgery, Okayama University Graduate School of Medicine, Kita-ku, Okayama, Japan.

Takashi Matsuki (T)

Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Minami-ku, Sagamihara, Japan.

Masato Nakaguro (M)

Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.

Yukiko Sato (Y)

Division of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.

Makoto Urano (M)

Department of Diagnostic Pathology, Bantane Hospital, Fujita Health University, School of Medicine, Nakagawa-ku, Nagoya, Japan.

Yoshitaka Utsumi (Y)

Department of Anatomic Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Shinji Kohsaka (S)

Division of Cellular Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.

Takashi Saotome (T)

Division of Medical Oncology, Matsudo City Hospital, Matsudo, Japan.

Yuichiro Tada (Y)

Department of Head and Neck Oncology and Surgery, International University of Health and Welfare, Mita Hospital, 1-4-3 Mita, Minato-ku, Tokyo 108-8329, Japan.
ORCID: 0000-0002-0159-8660

Classifications MeSH